On the stock market since 1991, it operates in the world of health and science. It has 11,000 employees. Now — the numbers.
This is an established company with proven profits.
The gap is $897.1M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 26% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 25% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 9% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
The company’s market value is 42 times its annual profit. Even a small disappointment could hit the price hard.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 43/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, IDXX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: IDXX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (60/100) says the stock isn’t cheap.